GIBSON DUNN

Gibson Dunn Advises Jade Biosciences on Merger with Aerovate Therapeutics, Inc. and Concurrent Private Placement

Firm News | October 31, 2024

Gibson Dunn is advising Jade Biosciences on its merger with Aerovate Therapeutics, Inc. and the concurrent $300 million private placement of shares of its common stock and pre-funded warrants to a syndicate of healthcare investors. The Gibson Dunn corporate team includes partners Ryan Murr, Branden Berns and Chris Trester and associates Evan Shepherd and Candice Johnson.

Related People

Ryan A. Murr

Branden C. Berns

Chris W. Trester

Evan Shepherd

Candice D. Johnson

Related Capabilities

Mergers and Acquisitions

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**